A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

NCT01853722 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Ocular Infection

Interventions

DRUG: DCN01
DRUG: Unisol

Sponsor

Deacon Biosciences, Inc.

Collaborators

[object Object]